参麦注射液联合替吉奥对晚期胃癌患者T细胞亚群及血清CA72-4和G17的影响

Effects of Shenmai injection combined with tegafur on T lymphocyte subsets and serum CA72-4 and G17 levels in patients with advanced gastric cancer

目的探讨参麦注射液联合替吉奥对晚期胃癌患者T淋巴细胞亚群、血清糖类抗原72-4(CA72-4)及胃泌素17(G17)水平变化的影响。方法选取2013年10月至2016年4月间湖南旺旺医院收治的62例晚期胃癌患者,采用随机数表法分为研究组与对照组,每组31例。研究组患者采用替吉奥胶囊和参麦注射液治疗,对照组患者采用替吉奥胶囊治疗。疗程结束后比较两组患者临床疗效、不良反应发生率,并对入院时及疗程结束后两组患者血清CA72-4、G17及T淋巴细胞(CD3+、CD4+、CD8+和CD4+/CD8+)的变化情况进行比较。结果研究组患者治疗总有效率为58.1%,高于对照组患者的32.3%,差异有统计学意义(P<0.05)。治疗前,两组患者的CD3+、CD4+、CD8+及CD4+/CD8+比较,差异无统计学意义(P>0.05)。治疗后,研究组患者的CD3+、CD4+和CD4+/CD8+高于对照组患者,CD8+低于对照组患者,差异均有统计学意义(均P<0.05)。治疗后,两组患者的血清CA72-4和G17水平较治疗前降低,且研究组低于对照组,差异均有统计学意义(均P<0.05)。研究组患者的血小板减少率、白细胞减少率、贫血率及呕吐恶心率均低于对照组患者,差异均有统计学意义(均P<0.05)。结论参麦注射液联合替吉奥治疗晚期胃癌效果显著,可有效降低患者血清CA72-4和G17水平,增强患者机体免疫功能,提高治疗效果,减少不良反应。

Objective To investigate the effect of Shenmai injection combined with tegafur on T lymphocyte subsets and serum carbohydrate antigens 72-4（ CA72-4） and gastrin 17（ G17） in patients with advanced gastric cancer. Methods From October 2013 to April 2016,62 patients with advanced gastric cancer treated at Hunan Wangwang Hospital were selected and randomly divided into a study group and a control group using a random number table with 31 patients in each group. The study group was treated with tegafur capsule plus Shenmai injection and the control group was treated with single tegafur capsule. Clinical efficacy and the incidence of adverse reactions were compared between the two groups at the end of the study. Changes in serum CA72-4,G17 levels and T lymphocyte subsets（ CD3^＋,CD4^＋,CD8^＋and CD4^＋/CD8^＋） were statistically compared between the two groups at admission and after the treatment.Results The overall efficacy rate was 58. 1% for the study group which was higher than 32. 3% of the control group（ P〈0. 05）. There was no significant difference in CD3^＋,CD4^＋,CD8^＋and CD4^＋/CD8^＋between the two groups before the treatment（ P〉0. 05）. However,after treatment,the levels of CD3^＋,CD4^＋and CD4^＋/CD8^＋were significantly higher in the study group than in the control group and CD8^＋was significantly lower in the study group than in the control group（ all P〈0. 05）. The serum CA72-4 and G17 levels decreased in the two groups after the treatment compared with before the treatment,with the study group lower than the control group（ all P〈0. 05）. The rates of thrombocytopenia,leukopenia,anemia and the vomiting and nausea were lower in the study group than in the control group（ all P〈0. 05）.Conclusion Shenmai injection combined with tegafur in the treatment of advanced gastric cancer shows significant efficacy,which can effectively reduce the serum CA72-4 and G17 levels,enhance immune function,improve the treatment efficacy and reduce adverse reactions.